Document is current
Any future updates will be listed below
-
Authors
Xu, Shishi
Coleman, Ruth L.
Wan, Qin
Gu, Yeqing
Meng, Ge
Song, Kun
Shi, Zumin
Xie, Qian
Tuomilehto, Jaakko
Holman, Rury R.
Niu, Kaijun
Tong, Nanwei
-
Funding
Funding for this research was provided by:
1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYGD18017)
- License Information
-
More Information
Article History
Received: 11 April 2022
Accepted: 7 September 2022
First Online: 13 September 2022
Declarations
:
: The ACE protocol was approved by the University of Oxford Tropical Research Ethics Committee, and by central or local ethics committees (as appropriate) at participating sites. The protocol of the Luzhou and TCLSIH cohorts was approved by the Medical Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University (Shanghai, China), and Institutional Review Board of Tianjin Medical University (Tianjin, China) respectively. Written informed consent was obtained from all participants.
: Not applicable.
: SX, RLC, QW, YG, GM, KS, ZS, QX, KN, and NT have no disclosures. JT reports research grants and fees for consultancy and advisory board membership from Bayer AG (related to the present study) and Eli Lilly, and he owns stocks in Orion Pharma and Aktivolabs. RRH reports research support from AstraZeneca, Bayer and Merck Sharp & Dohme, and personal fees from Bayer, Intarcia, Merck Sharp & Dohme, Novartis and Novo Nordisk.
